US EditionLong-Acting HIV PrEP Drug Lenacapavir Approved – But Access Is Vital, Say Health Bodies
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.10 Articles
10 Articles
Long-Acting HIV PrEP Drug Lenacapavir Approved – But Access Is Vital, Say Health Bodies
Australia has taken another regulatory step in HIV prevention, with the Therapeutic Goods Administration (TGA) approving the long-acting HIV drug lenacapavir for use as pre-exposure prophylaxis (PrEP). The twice-yearly injectable ... The post Long-Acting HIV PrEP Drug Lenacapavir Approved – But Access Is Vital, Say Health Bodies appeared first on Star Observer.
The National Sanitary Vigilance Agency (Anvisia) approved this afternoon 12 the use of Sunlenca (lenacapavir) for HIV prevention in Brazil. The authorisation is valid for pre-exposure prevention (PrEP), a strategy for people who do not have the virus but are at risk of contracting infection. According to Anvisa, the medicine is highly effective and is available in two forms: oral use tablet, used at the beginning of treatment, and subcutaneous i…
The National Sanitary Vigilance Agency (Anvisia) approved on this Tuesday (12) the use of the commercial name of lenacapavir as an option for pre-exposure prevention (PrP) to HIV. The medicine is indicated, according to the Agency, “adults and adolescents from 12 years of age at least 35 kg who are at risk of contracting the virus”. The drug is available in the forms of tablets, to be used at the beginning of treatment, and injection administere…
The National Sanitary Vigilance Agency (Anvisia) approved this afternoon (12) the use of Sunlenca (lencapavir) for HIV-1 prevention, as pre-exposure prevention (PrEP). The drug has high efficacy against the virus and, in addition to the compromise, for oral use, is available as subcutaneous injection that only needs to be administered every six months, which facilitates accession. The indication is intended for adults and adolescents from 12 yea…
Brazil's National Health Surveillance Agency (Anvisa) approved on Monday (January 12, 2026) the registration of injectable lenacapavir for PrEP (pre-exposure prophylaxis) against HIV. The drug, commercially known as Sunlenca, represents a milestone in disease prevention as it requires only two annual applications, serving as an alternative to daily pills. It is indicated for adults and adolescents over 12 years of age (weighing at least 35 kg) w…
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
